Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical Reviews in Allergy & Immunology
Published in: Clinical Reviews in Allergy & Immunology 2/2012

01-04-2012

Prolactin and Autoimmunity

Hyperprolactinemia Correlates with Serositis and Anemia in SLE Patients

Authors: Hedi Orbach, Gisele Zandman-Goddard, Mona Boaz, Nancy Agmon-Levin, Howard Amital, Zoltan Szekanecz, Gabriella Szucs, Josef Rovensky, Emese Kiss, Andrea Doria, Anna Ghirardello, Jesus Gomez-Arbesu, Ljudmila Stojanovich, Francesca Ingegnoli, Pier Luigi Meroni, Blaz’ Rozman, Miri Blank, Yehuda Shoenfeld

Published in: Clinical Reviews in Allergy & Immunology | Issue 2/2012

Login to get access

Abstract

Evidence points to an association of prolactin to autoimmune diseases. We examined the correlation between hyperprolactinemia and disease manifestations and activity in a large patient cohort. Age- and sex-adjusted prolactin concentration was assessed in 256 serum samples from lupus patients utilizing the LIASON prolactin automated immunoassay method (DiaSorin S.p.A, Saluggia, Italy). Disease activity was defined as present if European Consensus Lupus Activity Measurement (ECLAM) > 2 or Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) > 4. Lupus manifestations were grouped by organ involvement, laboratory data, and prescribed medications. Hyperprolactinemia was presented in 46/256 (18%) of the cohort. Hyperprolactinemic patients had significantly more serositis (40% vs. 32.4%, p = 0.03) specifically, pleuritis (33% vs. 17%, p = 0.02), pericarditis (30% vs. 12%, p = 0.002), and peritonitis (15% vs. 0.8%, p = 0.003). Hyperprolactinemic subjects exhibited significantly more anemia (42% vs. 26%, p = 0.02) and marginally more proteinuria (65.5% vs. 46%, p = 0.06). Elevated levels of prolactin were not significantly associated with other clinical manifestations, serology, or therapy. Disease activity scores were not associated with hyperprolactinemia. Hyperprolactinemia in lupus patients is associated with all types of serositis and anemia but not with other clinical, serological therapeutic measures or with disease activity. These results suggest that dopamine agonists may be an optional therapy for lupus patients with hyperprolactinemia.
Literature
1.
De Schepper J, Schiettecatte J, Velkeniers B et al (2003) Clinical and biological characterization of macroprolactinemia with and without prolactin-IgG complexes. Eur J Endocrinol 149:201–207PubMedCrossRef
2.
Freeman ME, Kanyicska B, Lerant A, Nagy G (2000) Prolactin: structure, function, and regulation of secretion. Physiol Rev 80:1523–1631PubMed
3.
Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA (1998) Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev 19:225–258PubMedCrossRef
4.
Chikanza IC (1999) Prolactin and neuroimmunomodulation: in vitro and in vivo observations. Ann NY Acad Sci 876:119–130PubMedCrossRef
5.
Serri O, Chik CL, Ur E, Ezzat S (2003) Diagnosis and management of hyperprolactinemia. Can Med Assoc J 169:575–581
6.
Jara LJ, Medina G, Saavedra MA, Vera-Lastra O, Navarro C (2011) Prolactin and autoimmunity. Clin Rev Allergy Immunol 40:50–59PubMedCrossRef
7.
Adamson AD, Friedrichsen S, Semprini S et al (2008) Human prolactin gene promoter regulation by estrogen: convergence with tumor necrosis factor-alpha signaling. Endocrinology 149:687–694PubMedCrossRef
8.
9.
Walker SE, Jacobson JD (2000) Roles of prolactin and gonadotropin-releasing hormone in rheumatic diseases. Rheum Dis Clin North Am 26:713–736PubMedCrossRef
10.
Thoreau E, Petridou B, Kelly PA, Djiane J, Mornon JP (1991) Structural symmetry of the extracellular domain of the cytokine/growth hormone/prolactin receptor family and interferon receptors revealed by hydrophobic cluster analysis. FEBS Lett 282:26–31PubMedCrossRef
11.
Ben-Jonathan N, Mershon JL, Allen DL, Steinmetz RW (1996) Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. Endocr Rev 17:639–669PubMed
12.
Peeva E, Zouali M (2005) Spotlight on the role of hormonal factors in the emergence of autoreactive B-lymphocytes. Immunol Lett 101:123–143PubMedCrossRef
13.
Saha S, Gonzalez J, Rosenfeld G, Keiser H, Peeva E (2009) Prolactin alters the mechanisms of B cell tolerance induction. Arthritis Rheum 60:1743–1752PubMedCrossRef
14.
Athreya BH, Pletcher J, Zulian F, Weiner DB, Williams WV (1993) Subset-specific effects of sex hormones and pituitary gonadotropins on human lymphocyte proliferation in vitro. Clin Immunol Immunopathol 66:201–211PubMedCrossRef
15.
Sousa GM, Olivera RC, Perelra MM, Paraná R, Sousa-Atta ML, Atta AM (2010) Autoimmunity in hepatitis C virus carriers: involvement of ferritin and prolactin. Autoimmun Rev (in press)
16.
Jara LJ, Benitez G, Medina G (2008) Prolactin, dendritic cells, and systemic lupus erythematosus. Autoimmun Rev 7:251–255PubMedCrossRef
17.
Lahat N, Miller A, Shtiller R, Toubi E (1993) Differential effects of prolactin upon activation and differentiation of human B lymphocytes. J Neuroimmunol 47:35–40PubMedCrossRef
18.
19.
Cejkova P, Fojtikova M, Cerna M (2009) Immunomudulatory role of prolactin in diabetes mellitus. Autoimmun Rev 9:23–27PubMedCrossRef
20.
Jara LJ, Gomez-Sanchez C, Silveira LH, Martinez-Osuna P, Vasey FB, Espinoza LR (1992) Hyperprolactinemia in systemic lupus erythematosus: association with disease activity. Am J Med Sci 303:222–226PubMedCrossRef
21.
Allen SH, Sharp GC, Wang G et al (1996) Prolactin levels and antinuclear antibody profiles in women tested for connective tissue disease. Lupus 5:30–37PubMed
22.
Buskila D, Lorber M, Neumann L, Flusser D, Shoenfeld Y (1996) No correlation between prolactin levels and clinical activity in patients with systemic lupus erythematosus. J Rheumatol 23:629–632PubMed
23.
Alvarez-Nemegyei J, Cobarrubias-Cobos A, Escalante-Triay F et al (1998) Bromocriptine in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled study. Lupus 7:414–419PubMedCrossRef
24.
Szyper-Kravitz M, Zandman-Goddard G, Lahita RG, Shoenfeld Y (2005) The neuroendocrine-immune interactions in systemic lupus erythematosus: a basis for understanding disease pathogenesis and complexity. Rheum Dis Clin North Am 31:161–175PubMedCrossRef
25.
Leanos-Miranda A, Cardenas-Mondragon G (2006) Serum free prolactin concentrations in patients with systemic lupus erythematosus are associated with lupus activity. Rheumatology 45:97–101PubMedCrossRef
26.
Rezaieyazdi Z, Hesamifard A (2006) Correlation between serum prolactin levels and lupus activity. Rheumatol Int 26:1036–1039PubMedCrossRef
27.
El Miedany YM, Ahmed I, Moustafa H, El Baddini M (2004) Hyperprolactinemia in Sjogren’s syndrome: a patient subset or a disease manifestation? Joint Bone Spine 71:203–208PubMedCrossRef
28.
Peeva E (2011) Reproductive immunology: a focus on the role of female sex hormones and other gender-related factors. Clin Rev Allergy Immunol 40:1–7PubMedCrossRef
29.
Blank M, Krause I, Buskila D et al (1995) Bromocriptine immunomodulation of experimental SLE and primary antiphospholipid syndrome via induction of nonspecific T suppressor cells. Cell Immunol 162:114–122PubMedCrossRef
30.
Peeva E, Grimaldi C, Spatz L, Diamond B (2000) Bromocriptine restores tolerance in estrogen-treated mice. J Clin Invest 106:1373–1379PubMedCrossRef
31.
32.
McMurray RW, Weidensaul D, Allen SH, Walker SE (1995) Efficacy of bromocriptine in an open label therapeutic trial for systemic lupus erythematosus. J Rheumatol 22:2084–2091PubMed
33.
Jara LJ, Cruz-Cruz P, Saavedra MA et al (2007) Bromocriptine during pregnancy in systemic lupus erythematosus. A pilot clinical trial. Ann NY Acad Sci 1110:297–304PubMedCrossRef
34.
Hrycek A, Pochopien-Kenig G, Cieszka J (2007) Selected acute phase proteins and interleukin-6 in systemic lupus erythematosus patients treated with low doses of quinagolide. Autoimmunity 40:217–222PubMedCrossRef
35.
Fojtíková M, Tomasová Studýnková J, Filková M et al (2010) Elevated prolactin levels in patients with rheumatoid arthritis: association with disease activity and structural damage. Clin Exp Rheumatol 28:849–854PubMed
36.
Olsen NJ, Kovacs WJ (2002) Hormones, pregnancy, and rheumatoid arthritis. J Gend-Specif Med 5:28–37PubMed
37.
Brennan P, Ollier B, Worthington J, Hajeer A, Silman A (1996) Are both genetic and reproductive associations with rheumatoid arthritis linked to prolactin? Lancet 348:106–109PubMedCrossRef
38.
Jorgensen C, Bressot N, Bologna C, Sany J (1995) Dysregulation of the hypothalamo-pituitary axis in rheumatoid arthritis. J Rheumatol 22:1829–1833PubMed
39.
Templ E, Koeller M, Riedl M, Wagner O, Graninger W, Luger A (1996) Anterior pituitary function in patients with newly diagnosed rheumatoid arthritis. Br J Rheumatol 35:350–356PubMedCrossRef
40.
Zoli A, Lizzio MM, Ferlisi EM et al (2002) ACTH, cortisol and prolactin in active rheumatoid arthritis. Clin Rheumatol 21:289–293PubMedCrossRef
41.
Eijsbouts AM, van den Hoogen FH, Laan RF, Sweep CG, Hermus AR, van de Putte LB (2005) Decreased prolactin response to hypoglycaemia in patients with rheumatoid arthritis: correlation with disease activity. Ann Rheum Dis 64:433–437PubMedCrossRef
42.
Rovensky J, Imrich R, Malis F et al (2004) Prolactin and growth hormone responses to hypoglycemia in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol 31:2418–2421PubMed
43.
Kullich WC, Klein G (1998) High levels of macrophage inflammatory protein-1alpha correlate with prolactin in female patients with active rheumatoid arthritis. Clin Rheumatol 17:263–264PubMedCrossRef
44.
Nagafuchi H, Suzuki N, Kaneko A, Asai T, Sakane T (1999) Prolactin locally produced by synovium infiltrating T lymphocytes induces excessive synovial cell functions in patients with rheumatoid arthritis. J Rheumatol 26:1890–1900PubMed
45.
Cutolo M, Balleari E, Giusti M, Monachesi M, Accardo S (1986) Sex hormone status in women suffering from rheumatoid arthritis. J Rheumatol 13:1019–1023PubMed
46.
Gutierrez MA, Garcia ME, Rodriguez JA, Mardonez G, Jacobelli S, Rivero S (1999) Hypothalamic-pituitary-adrenal axis function in patients with active rheumatoid arthritis: a controlled study using insulin hypoglycemia stress test and prolactin stimulation. J Rheumatol 26:277–281PubMed
47.
Ram S, Blumberg D, Newton P, Anderson NR, Gama R (2004) Raised serum prolactin in rheumatoid arthritis: genuine or laboratory artefact? Rheumatol (Oxford) 43:1272–1274CrossRef
48.
Seriolo B, Ferretti V, Sulli A, Fasciolo D, Cutolo M (2002) Serum prolactin concentrations in male patients with rheumatoid arthritis. Ann NY Acad Sci 966:258–262PubMedCrossRef
49.
Mateo L, Nolla JM, Bonnin MR, Navarro MA, Roig-Escofet D (1998) High serum prolactin levels in men with rheumatoid arthritis. Rheumatol 25:2077–2082
50.
Orbach H, Zandman-Goddard G, Amital H et al (2007) Novel biomarkers in autoimmune diseases: prolactin, ferritin, vitamin D, and TPA levels in autoimmune diseases. Ann NY Acad Sci 1109:385–400PubMedCrossRef
51.
Dougados M, Duchesne L, Amor B (1988) Bromocriptine and cyclosporin A combination therapy in rheumatoid arthritis. Arthritis Rheum 31:1333–1334PubMedCrossRef
52.
Marguerie C, David J, So A, Walport M (1990) A pilot study comparing bromocriptine with D-penicillamine in the treatment of rheumatoid arthritis. Br J Rheumatol 29(suppl 2):3
53.
Mader R (1997) Bromocriptine for refractory rheumatoid arthritis. Harefuah 133:527–529PubMed
54.
Figueroa F, Carrion F, Martinez M, Rivero S, Mamani I (1997) Bromocriptine induces immunological changes related to disease parameters in rheumatoid arthritis. Br J Rheumatol 36:1022–1027PubMedCrossRef
55.
Eijsbouts A, van den Joogen F, Laan R, Hermus A, Sweep F, van de Putte L (1999) Treatment of rheumatoid arthritis with the dopamine agonist quinagolide. J Rheumatol 26:2284–2285PubMed
56.
Erb N, Pace A, Delamere J, Kitas G (2001) Control of unremitting rheumatoid arthritis by the prolactin antagonist cabergoline. Rheumatology 40:237–239PubMedCrossRef
57.
Riskind PN, Massacesi L, Doolittle TH, Hauser SL (1991) The role of prolactin in autoimmune demyelination: suppression of experimental allergic encephalomyelitis by bromocriptine. Ann Neurol 29:542–527PubMedCrossRef
58.
Dijkstra CD, van der Voort ER, De Groot CJ et al (1994) Therapeutic effect of the D2-dopamine agonist bromocriptine on acute and relapsing experimental allergic encephalomyelitis. Psychoneuroendocrinology 19:135–142PubMedCrossRef
59.
Kira J, Harada M, Yamaguchi Y, Shida N, Goto I (1991) Hyperprolactinemia in multiple sclerosis. J Neurol Sci 102:61–66PubMedCrossRef
60.
Azar ST, Yamout B (1999) Prolactin secretion is increased in patients with multiple sclerosis. Endocrin Res 25:207–214CrossRef
61.
Zych-Twardowska E, Wajgt A (1999) Serum prolactin and sex hormone concentrations in patients withmultiple sclerosis. Med Sci Monit 5:216–220
62.
Yamasaki K, Horiuchi I, Minohara M et al (2000) Hyperprolactinemia in optico-spinal multiple sclerosis. Intern Med 39:296–299PubMedCrossRef
63.
Safarinejad MR (2008) Evaluation of endocrine profile, hypothalamic–pituitary–testis axis and semen quality in multiple sclerosis. J Neuroendocrinol 20:1368–1375PubMedCrossRef
64.
Markianos M, Koutsis G, Evangelopoulos ME, Mandellos D, Sfagos C (2010) Serum and cerebrospinal fluid prolactin levels in male and female patients with clinically-isolated syndrome or relapsing-remitting multiple sclerosis. J Neuroendocrinol 22:503–508PubMedCrossRef
65.
Da Costa R, Szyper-Kravitz M, Szekanecz Z et al. (2011) Ferritin and prolactin levels in multiple sclerosis. Isr Med Assoc J (in press)
66.
Nociti V, Frisullo G, Tartaglione T et al (2010) Multiple sclerosis attacks triggered by hyperprolactinemia. J Neurooncol 98:407–409PubMedCrossRef
67.
RederAT LMT (1993) Serum prolactin levels in active multiple sclerosis and during cyclosporin treatment. J Neurol Sci 117:192–196CrossRef
68.
Wei T, Lightman SL (1997) The neuroendocrine axis in patients with multiple sclerosis. Brain 120:1067–1076PubMedCrossRef
69.
Heesen C, Gold SM, Bruhn M, Mönch A, Schulz KH (2002) Prolactin stimulation in multiple sclerosis—an indicator of disease subtypes and activity? Endocr Res 28:9–18PubMedCrossRef
70.
Harirchian MH, Sahralan MA, Shirani A (2006) Serum prolactin level in patients with multiple sclerosis: a case control study. Med Sci Monit 12:177–180
71.
Bissay V, De Klippelm N, Herroelenm L et al (1994) Bromocriptine therapy in multiple sclerosis: an open label pilot study. Clin Neuropharmacol 17:473–476PubMedCrossRef
72.
Then Bergh F, Kuemple T, Schumann E et al (2006) Monthly i.v. methylprednisolone in relapsing remitting MS-reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations. BMC Neurol 23:19CrossRef
73.
74.
Hilty C, Brühlmann P, Sprott H et al (2000) Altered diurnal rhythm of prolactin in systemic sclerosis. J Rheumatol 27:2160–2165PubMed
75.
Shahin AA, Abdoh S, Abdelrazik M (2002) Prolactin and thyroid hormones in patients with systemic sclerosis: correlations with disease manifestations and activity. Z Rheumatol 61:703–709PubMedCrossRef
76.
Czuwara-Ladykowska J, Sicinska J, Olszewska M, Uhrynowska-Tyszkiewicz I, Rudnicka L (2006) Prolactin synthesis by lymphocytes from patients with systemic sclerosis. Biomed Pharmacother 60:152–155PubMedCrossRef
77.
La Montagna G, Baruffo A, Pasquali D, Bellastella A, Tirri G, Sinisi AA (2001) Assessment of pituitary gonadotropin release to gonadotropin releasing hormone/thyroid-stimulating hormone stimulation in women with systemic sclerosis. Rheumatol (Oxford) 40:310–314CrossRef
78.
Vera-Lastra O, Jara LJ, Medina G et al (2006) Functional hyperprolactinemia and hypophyseal microadenoma in systemic sclerosis. J Rheumatol 33:1108–1112PubMed
79.
Straub RH, Zeuner M, Lock G, Schölmerich J, Lang B (1997) High prolactin and low dehydroepiandrosterone sulphate serumlevels in patients with severe systemic sclerosis. Br J Rheumatol 36:426–432PubMedCrossRef
80.
Buskila D, Berezin M, Gur H et al (1995) Autoantibody profile in the sera of women with hyperprolactinemia. J Autoimmun 8:415–424PubMedCrossRef
81.
Haga HJ, Rygh T (1999) The prevalence of hyperprolactinemia in patients with primary Sjögren’s syndrome. J Rheumatol 26:1291–1295PubMed
82.
Gutiérrez MA, Anaya JM, Scopelitis E, Citera G, Silveira L, Espinoza LR (1994) Hyperprolactinaemia in primary Sjögren’s syndrome. Ann Rheum Dis 53:425PubMedCrossRef
83.
Steinfeld S, Rommes S, François C et al (2000) Big prolactin 60 kDa is overexpressed in salivary glandular epithelial cells from patients with Sjögren’s syndrome. Lab Invest 80:239–247PubMedCrossRef
84.
Johnson EO, Moutsopoulos HM (2000) Neuroendocrine manifestationsin Sjögren’s syndrome. Relation to the neurobiology of stress. Ann NY Acad Sci 917:797–808PubMedCrossRef
85.
Legakis I, Petroyianni V, Saramantis A, Tolis G (2001) Elevated prolactin to cortisol ratio and polyclonal autoimmune activation in Hashimoto’s thyroiditis. Horm Metab Res 33:585–589PubMedCrossRef
86.
Notsu K, Ito Y, Furuya H, Ohguni S, Kato Y (1997) Incidence of hyperprolactinemia in patients with Hashimoto’s thyroiditis. Endocr J 44:89–94PubMedCrossRef
87.
Poyraz BC, Aksoy C, Balcıoğlu I (2008) Increased incidence of autoimmune thyroiditis in patients with antipsychotic-induced hyperprolactinemia. Europ Neuropsychopharmacol 18:667–672CrossRef
88.
Ward MM, Marx AS, Barry NN (2000) Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus. J Rheumatol 27:664–670PubMed
89.
Jacobi AM, Rohde W, Ventz M, Riemekasten G, Burmester GR, Hiepe F (2001) Enhanced serum prolactin (PRL) in patients with systemic lupus erythematosus: PRL levels are related to the disease activity. Lupus 10:554–561PubMedCrossRef
90.
Leaños-Miranda A, Pascoe-Lira D, Chávez-Rueda KA, Blanco-Favela F (2001) Antiprolactin autoantibodies in systemic lupus erythematosus: frequency and correlation with prolactinemia and disease activity. J Rheumatol 28:1546–1553PubMed
91.
Paciliom M, Migliaresim S, Melim R, Ambrosonem L, Bigliardom B, Di Carlo R (2001) Elevated bioactive prolactin levels in systemic lupus erythematosus-association with disease activity. J Rheumatol 28:2216–2221
92.
Shabanova SS, Ananieva LP, Alekberova ZS, Guzov II (2008) Ovarian function and disease activity in patients with systemic lupus erythematosus. Clin Exp Rheumatol 26:436–441PubMed
93.
McMurray R, Keisler D, Kanuckel K, Izui S, Walker SE (1991) Prolactin influences autoimmune disease activity in the female B/W mouse. J Immunol 147:3780–3787PubMed
94.
McMurray R, Keisler D, Izui S, Walker SE (1994) Hyperprolactinemia in male NZB/NZW (B/W) F1 mice: accelerated autoimmune disease with normal circulating testosterone. Clin Immunol Immunopathol 71:338–343PubMedCrossRef
95.
Rovenský J, Juránková E, Rauová L et al (1997) Relationship between endocrine, immune, and clinical variables in patients with systemic lupus erythematosus. J Rheumatol 24:2330–2334PubMed
96.
Ferreira C, Paes M, Gouveia A, Ferreira E, Padua F, Fiuza T (1998) Plasma homovanillic acid and prolactin in systemic lupus erythematosus. Lupus 7:392–397PubMedCrossRef
97.
Jimena P, Aguirre MA, Lopez-Curbelo A, de Andres M, Garcia-Courtay C, Cuadrado MJ (1998) Prolactin levels in patient with systemic lupus erythematosus: a case controlled study. Lupus 7:383–386PubMedCrossRef
98.
Blanco-Favela F, Quintal-Alvarez G, Leanos-Miranda A (1999) Association between prolactin and disease activity in systemic lupus erythematosus. Influence of statistical power. J Rheumatol 26:55–59PubMed
99.
Leanos-Miranda A, Chavez-Rueda KA, Blanco-Favela F (2001) Biologic activity and plasma clearance of prolactin-IgG complex in patients with systemic lupus erythematosus. Arthritis Rheum 44:866–875PubMedCrossRef
100.
Leanos A, Pascoe D, Fraga A, Blanco-Favela F (1998) Anti-prolactin autoantibodies in systemic lupus erythematosus patients with associated hyperprolactinemia. Lupus 7:398–403PubMedCrossRef
101.
Jara LJ, Vera-Lastra O, Miranda JM, Alcala M, Alvarez-Nemegyei J (2001) Prolactin in human systemic lupus erythematosus. Lupus 10:748–756PubMedCrossRef
102.
Jara LJ, Irigoyen L, de Ortiz MJ, Zazueta B, Bravo G, Espinoza LR (1998) Prolactin and interleukin-6 in neuropsychiatric lupus erythematosus. Clin Rheumatol 17:110–114PubMedCrossRef
103.
Zoli A, Ferlisi EM, Pompa A et al (1999) Basal and after-stimuli test for prolactinemia in systemic lupus erythematosus. Ann NY Acad Sci 876:155–158PubMedCrossRef
104.
Rastin M, Hatef MR, Tabasi N, Sheikh AM, Abbasi J, Mahmoudi M (2007) Sex hormones and peripheral white blood cell subsets in systemic lupus erythematosus patients. Iran J Immunol 4:110–115PubMed
105.
Praprotnik S, Agmon-Levin N, Porat-Katz BS et al (2010) Prolactin’s role in the pathogenesis of the antiphospholipid syndrome. Lupus 19:1515–1519PubMedCrossRef
106.
Alarcón-Segovia D (2001) The future of treatment for systemic lupus erythematosus. Isr Med Assoc J 3:127–130PubMed
Metadata
Title
Prolactin and Autoimmunity
Hyperprolactinemia Correlates with Serositis and Anemia in SLE Patients
Authors
Hedi Orbach
Gisele Zandman-Goddard
Mona Boaz
Nancy Agmon-Levin
Howard Amital
Zoltan Szekanecz
Gabriella Szucs
Josef Rovensky
Emese Kiss
Andrea Doria
Anna Ghirardello
Jesus Gomez-Arbesu
Ljudmila Stojanovich
Francesca Ingegnoli
Pier Luigi Meroni
Blaz’ Rozman
Miri Blank
Yehuda Shoenfeld
Publication date
01-04-2012
Publisher
Humana Press Inc
Published in
Clinical Reviews in Allergy & Immunology / Issue 2/2012
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-011-8256-0

Other articles of this Issue 2/2012

Clinical Reviews in Allergy & Immunology 2/2012 Go to the issue

ReviewPaper

Cutting-Edge Issues in Autoimmune Orchitis

OriginalPaper

Long-Term Therapy with Intravenous Immunoglobulin is Beneficial in Patients with Autoimmune Diseases

OriginalPaper

Infectious Serologies and Autoantibodies in Hepatitis C and Autoimmune Disease-Associated Mixed Cryoglobulinemia

OriginalPaper

Geographical Differences in Autoantibodies and Anti-infectious Agents Antibodies Among Healthy Adults

ReviewPaper

The Etiology of Paraneoplastic Autoimmunity

ReviewPaper

Guillain–Barré Syndrome—A Classical Autoimmune Disease Triggered by Infection or Vaccination
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits